DISTILLATION №19 — MOTS-c K13R (MRWQEMGYIFYPRRLR)

Verdict: PROMISING | pLDDT 0.627 | ipTM 0.499 | Class: LONGEVITY

Mechanism of Action

MOTS-c is a 16-residue mitochondrial-derived peptide (MDP) encoded within the mitochondrial genome's 12S rRNA locus. Its primary described mechanism is metabolic rather than receptor-mediated: MOTS-c disrupts the intracellular folate-methionine cycle, causing accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), an endogenous allosteric activator of AMPK (5'-AMP-activated protein kinase). AMPK activation downstream of this cascade drives the full spectrum of MOTS-c's described bioactivities — improved glucose uptake in skeletal muscle, attenuation of insulin resistance, anti-obesity effects, bone metabolism regulation, and anti-inflammatory signaling.

Critically for this fold, the literature also documents that MOTS-c can engage protein targets through direct binding: its interaction with LARS1 (leucyl-tRNA synthetase 1) in an ovarian cancer context demonstrates that the peptide's surface chemistry participates in specific protein–protein contacts, not only metabolic perturbation. Under metabolic stress, MOTS-c also translocates to the nucleus and regulates adaptive gene expression directly. This dual — indirect metabolic and direct protein-binding — mode of action is the conceptual foundation for hypothesizing that optimizing MOTS-c's surface electrostatics could enhance target engagement potency.

Performance Applications

The MOTS-c K13R variant, if validated, would target the same therapeutic and performance contexts as native MOTS-c:

• Metabolic health & insulin sensitivity: AMPK activation in skeletal muscle is the primary mechanism; improved engagement could translate to more potent glucose disposal and insulin sensitization
• Longevity / metabolic aging: MOTS-c's AMPK-activating role connects directly to longevity pathways (FOXO signaling, mitophagy, mitochondrial biogenesis)
• Gestational diabetes and reproductive metabolic disorders: MOTS-c efficacy in gestational diabetes models (PMID:34798268) is AMPK-dependent; a more potent analog would be directly relevant
• Oncology support: Direct protein-binding capability (LARS1) suggests K13R may modulate cancer-relevant interactions; cationic patch optimization could alter selectivity
• Pulmonary and cardiac applications: MOTS-c studies in pulmonary fibrosis (PMID:37307934) and atrial fibrillation contexts depend on AMPK and mitochondrial protection pathways

Performance biohacking applications center on metabolic optimization, exercise recovery (AMPK-driven adaptations), and potential healthy aging support — consistent with the LONGEVITY classification.

Modification Rationale

Native MOTS-c (MRWQEMGYIFYPRKLR) carries a mixed cationic C-terminal cluster: Arg-12, Lys-13, Leu-14, Arg-16. The K13R substitution (→ MRWQEMGYIFYPRRRLR... correctly: MRWQEMGYIFYPRRRLR — specifically MRWQEMGYIFYPRRLR) converts this mixed tail into a uniform Arg-Leu-Arg arrangement, homogenizing the positive charge chemistry without altering residue count, charge state, or hydrophobic core composition.

The biophysical rationale is well-grounded:

• Guanidinium vs. ammonium: Arg's guanidinium group (pKa ~12.5) remains protonated at physiological pH more reliably than Lys's ammonium (pKa ~10.5), providing more consistent positive charge in biological microenvironments
• Bidentate geometry: Guanidinium forms two simultaneous hydrogen bonds with carboxylate groups (bidentate salt bridges), geometrically constraining the contact and increasing dwell time at acidic protein surfaces
• Cation-π capacity: Arg participates in cation-π interactions with aromatic protein residues; Lys does so less effectively
• No structural disruption: K→R is among the most conservative natural substitutions — both are long, positively charged, flexible side chains with no core packing role at position 13

This parallels the conservative-substitution philosophy of Fold #5 (Met-1 → Nle), which applied an isosteric swap at the N-terminus to prevent oxidation without disrupting backbone geometry, yielding pLDDT 0.62 — essentially matched by this fold at 0.627. The design explicitly avoids the N-terminal D-amino acid failure mode seen in Fold #6 (Epitalon, pLDDT 0.34), applying instead a physiochemically homologous substitution at a solvent-exposed C-terminal residue.

Predicted Properties (Where Signal Is Moderate)

Key observations:

• The structural prediction is internally consistent with the conservative-substitution hypothesis: pLDDT 0.627 falls in the same moderate-confidence band as Fold #5, suggesting the backbone fold is not disrupted by K13R
• The ipTM of 0.499 represents a plausible but not definitive binding interface — the model generates a hypothesis-consistent complex geometry but cannot confirm it
• Low aggregation propensity (0.083) is favorable: despite increased Arg density, the 16-mer does not appear to gain aggregation-prone character, supporting solution behavior comparable to the native peptide
• The moderate stability score (0.452) and half-life estimate are unremarkable — no predicted stability gain from K13R alone, consistent with the substitution being charge-homogenizing rather than structure-hardening

The moderate signal here reflects a structurally credible prediction constrained by: (a) absence of multi-predictor consensus, (b) absence of affinity quantification, and (c) the fundamental uncertainty about whether MOTS-c engages AMPK alpha-2 directly at all.

What Would Strengthen This Signal

Computational next steps:

1. Chai-1 ensemble prediction of the K13R variant vs. native MOTS-c docked to AMPK alpha-2 — multi-predictor consensus would substantially increase confidence in the binding pose and allow direct structural comparison
2. Boltz-2 affinity module (when available for peptide-protein complexes) to generate a predicted ΔΔG for K13R vs. native, providing quantitative binding change hypothesis
3. Molecular dynamics (MD) simulation of the C-terminal cationic tail in the predicted complex — would reveal whether the Arg-13 guanidinium forms stable bidentate contacts or remains freely diffusing, directly testing the core hypothesis
4. Native MOTS-c baseline fold at identical conditions to directly compare pLDDT/ipTM metrics rather than relying on Fold #5 as a proxy (Fold #5 was N-terminal; the C-terminal environment may differ)
5. K13A (alanine scan) fold — a predicted null substitution that would establish whether K13 contributes to structural confidence at all, providing an in silico negative control

Experimental validation path:

1. AMPK alpha-2 activation assay (cell-free or cellular): Direct comparison of native MOTS-c vs. K13R in AICAR-independent conditions would test whether any component of MOTS-c's AMPK activation is direct and Arg-13-dependent
2. SPR or BLI binding kinetics against recombinant AMPK alpha-2: Would resolve the fundamental question of whether MOTS-c contacts AMPK directly and whether K13R improves kd (off-rate)
3. Cellular AMPK phosphorylation assay (pAMPK T172): Direct comparison in C2C12 myotubes or HEK293 cells expressing PRKAA2, controlling for AICAR-mediated indirect effects where possible
4. Protease stability panel: K→R is not expected to alter tryptic susceptibility (both are trypsin cleavage sites), but the relative stability of K13R vs. native in plasma should be confirmed experimentally
5. LARS1 binding comparison: Given MOTS-c's established direct interaction with LARS1, testing K13R vs. native in the LARS1 context would probe whether cationic patch optimization alters direct protein-binding selectivity and potency

Critical mechanistic experiment: If MOTS-c's AMPK activation is entirely indirect (folate cycle → AICAR → AMPK), then K13R may show equivalent AMPK activation to native in cellular assays but potentially differ in cell-penetrating efficiency, nuclear translocation rate, or LARS1-like direct interactions. Distinguishing these pathways experimentally would determine whether the K13R modification is functionally meaningful and through which mechanism.